Clinical Trial News and Research

RSS

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade.

9 May 2014

Mice study shows specific energy source responsible for performing complex cognitive functions

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others.

9 May 2014

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention deficit hyperactivity disorder).

8 May 2014

Finding has implications for understanding cognitive decline in degenerative diseases

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others. The finding has implications for understanding the cognitive decline seen in aging and degenerative diseases such as Alzheimer's and multiple sclerosis.

8 May 2014

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

8 May 2014

MRI-guided focused ultrasound to treat pain from bone metastases

InSightec Ltd, the leader in magnetic resonance imaging guided Focused Ultrasound therapy (MRgFUS), announced that the results of its ExAblate® Phase III clinical trial for treating painful bone metastases have been published online in the JNCI, Journal of National Cancer Institute.

8 May 2014

WHI: Combined hormone therapy clinical trial yields massive economic return

Economic findings were released today on the Women's Health Initiative (WHI), estrogen plus progestin (E+P) trial.

8 May 2014

First international molecular screening program at IMPAKT for metastatic breast cancer

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored.

8 May 2014

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.

8 May 2014

Research may have "major implications" for treatment of urinary tract infections in children

A major new pediatric research study led by a Wayne State University researcher, funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) and published this week in the New England Journal of Medicine (NEJM), has "major implications" for the treatment of urinary tract infections (UTIs) in millions of American children.

8 May 2014

Low-carbohydrate diet reduces inflammation in patients with type 2 diabetes

A low-carbohydrate diet, but not a low-fat diet, reduces inflammation in patients with type 2 diabetes, according to research at Linköping University in Sweden.

8 May 2014

Common drug may improve blood flow in muscles of boys with Duchenne muscular dystrophy

A drug typically prescribed for erectile dysfunction or increased pressure in the arteries may help improve blood flow in the muscles of boys with Duchenne muscular dystrophy, according to a study published in the May 7, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

8 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2014.

7 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Clinical Trial News and Research

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

Mice study shows specific energy source responsible for performing complex cognitive functions

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Finding has implications for understanding cognitive decline in degenerative diseases

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

MRI-guided focused ultrasound to treat pain from bone metastases

WHI: Combined hormone therapy clinical trial yields massive economic return

First international molecular screening program at IMPAKT for metastatic breast cancer

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Research may have "major implications" for treatment of urinary tract infections in children

Low-carbohydrate diet reduces inflammation in patients with type 2 diabetes

Common drug may improve blood flow in muscles of boys with Duchenne muscular dystrophy

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ArQule reports net loss of $7,141,000 in first quarter 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Monthly injections to counteract AMD may not be necessary, say researchers

Loxo Oncology announces closing of $24 million Series B private financing round

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery